KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Operating Expenses: 2011-2024

Historic Operating Expenses for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to $557.0 million.

  • Travere Therapeutics' Operating Expenses rose 17.54% to $139.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $527.0 million, marking a year-over-year decrease of 6.03%. This contributed to the annual value of $557.0 million for FY2024, which is 4.43% up from last year.
  • As of FY2024, Travere Therapeutics' Operating Expenses stood at $557.0 million, which was up 4.43% from $533.4 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Operating Expenses ranged from a high of $557.0 million in FY2024 and a low of $331.3 million during FY2021.
  • Moreover, its 3-year median value for Operating Expenses was $533.4 million (2023), whereas its average is $506.6 million.
  • In the last 5 years, Travere Therapeutics' Operating Expenses fell by 11.54% in 2021 and then grew by 29.59% in 2022.
  • Over the past 5 years, Travere Therapeutics' Operating Expenses (Yearly) stood at $374.5 million in 2020, then fell by 11.54% to $331.3 million in 2021, then grew by 29.59% to $429.3 million in 2022, then increased by 24.25% to $533.4 million in 2023, then rose by 4.43% to $557.0 million in 2024.